Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $475.9 million.

  • Iovance Biotherapeutics' Non-Current Assets changed N/A to $475.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year change of. This contributed to the annual value of $453.4 million for FY2024, which is 404.12% down from last year.
  • Iovance Biotherapeutics' Non-Current Assets amounted to $475.9 million in Q3 2025.
  • Iovance Biotherapeutics' Non-Current Assets' 5-year high stood at $484.9 million during Q2 2025, with a 5-year trough of $187.0 million in Q1 2023.
  • In the last 3 years, Iovance Biotherapeutics' Non-Current Assets had a median value of $472.5 million in 2023 and averaged $440.5 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 15900.17% in 2024, then crashed by 623.71% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Non-Current Assets (Quarter) stood at $472.5 million in 2023, then decreased by 4.04% to $453.4 million in 2024, then rose by 4.95% to $475.9 million in 2025.
  • Its Non-Current Assets was $475.9 million in Q3 2025, compared to $484.9 million in Q2 2025 and $454.1 million in Q1 2025.